15108 Long-term efficacy and safety of dupilumab in adolescents with atopic dermatitis: Results from an open-label extension trial (LIBERTY AD PED-OLE)

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2020.06.653 ◽

2020 ◽

Vol 83 (6) ◽

pp. AB141

Author(s):

Andrew Blauvelt ◽

Emma Guttman ◽

Iftikhar Hussain ◽

Zhen Chen ◽

Paola Mina-Osorio ◽

...

Keyword(s):

Atopic Dermatitis ◽

Efficacy And Safety ◽

Term Efficacy ◽

Open Label Extension ◽

Extension Trial

Download Full-text

26880 Long-term efficacy and safety data for dupilumab in a phase 3, open-label extension trial (LIBERTY AD PED-OLE) in patients aged ≥6 to <12 years with uncontrolled, moderate-to-severe atopic dermatitis (AD)

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.06.499 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB120

Author(s):

Michael J. Cork ◽

Diamant Thaçi ◽

Lawrence Eichenfield ◽

Peter D. Arkwright ◽

Zhen Chen ◽

...

Keyword(s):

Atopic Dermatitis ◽

Safety Data ◽

Severe Atopic Dermatitis ◽

Efficacy And Safety ◽

Phase 3 ◽

Term Efficacy ◽

Open Label Extension ◽

Extension Trial

Download Full-text

Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up

British Journal of Dermatology ◽

10.1111/bjd.20595 ◽

2021 ◽

Author(s):

K.A. Papp ◽

M.G. Lebwohl ◽

L. Puig ◽

M. Ohtsuki ◽

S. Beissert ◽

...

Keyword(s):

Plaque Psoriasis ◽

Interim Analysis ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Term Efficacy ◽

Open Label Extension ◽

Extension Trial

Download Full-text

Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)

The Lancet Respiratory Medicine ◽

10.1016/s2213-2600(16)30430-1 ◽

2017 ◽

Vol 5 (1) ◽

pp. 51-60 ◽

Author(s):

Noel G McElvaney ◽

Jonathan Burdon ◽

Mark Holmes ◽

Allan Glanville ◽

Peter A B Wark ◽

...

Keyword(s):

Proteinase Inhibitor ◽

Efficacy And Safety ◽

Term Efficacy ◽

Antitrypsin Deficiency ◽

Open Label Extension ◽

Extension Trial ◽

Inhibitor Treatment

Download Full-text

Faculty Opinions recommendation of Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727072747.793539408 ◽

2017 ◽

Author(s):

Craig Hersh

Keyword(s):

Proteinase Inhibitor ◽

Efficacy And Safety ◽

Term Efficacy ◽

Antitrypsin Deficiency ◽

Open Label Extension ◽

Extension Trial ◽

Inhibitor Treatment

Download Full-text

Faculty Opinions recommendation of Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727479881.793555215 ◽

2019 ◽

Author(s):

Roser Torra

Keyword(s):

Kidney Disease ◽

Autosomal Dominant ◽

Efficacy And Safety ◽

Polycystic Kidney ◽

Delayed Treatment ◽

Open Label Extension ◽

Autosomal Dominant Polycystic Kidney ◽

Extension Trial

Download Full-text

Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study

Schizophrenia Research ◽

10.1016/j.schres.2021.11.030 ◽

2022 ◽

Vol 239 ◽

pp. 83-91

Author(s):

Yuriy Filts ◽

Robert E. Litman ◽

Javier Martínez ◽

Lourdes Anta ◽

Dieter Naber ◽

...

Keyword(s):

Extension Study ◽

Efficacy And Safety ◽

Term Efficacy ◽

Open Label Extension

Download Full-text

PS1221 LONG-TERM EFFICACY AND SAFETY OF INOTERSEN FOR HEREDITARY TRANSTHYRETIN AMYLOIDOSIS: NEURO-TTR OPEN-LABEL EXTENSION 2-YEAR UPDATE

10.1097/01.hs9.0000563168.52071.ab ◽

2019 ◽

Vol 3 (S1) ◽

pp. 557 ◽

Author(s):

T. Brannagan ◽

M. Waddington Cruz ◽

A.K. Wang ◽

M.J. Polydefkis ◽

P.J. Dyck ◽

...

Keyword(s):

Efficacy And Safety ◽

Transthyretin Amyloidosis ◽

Term Efficacy ◽

Open Label Extension ◽

Hereditary Transthyretin Amyloidosis

Download Full-text

P150 LONG-TERM EFFICACY AND SAFETY OF LANADELUMAB: FINAL RESULTS FROM THE HELP OPEN-LABEL EXTENSION STUDY

Annals of Allergy Asthma & Immunology ◽

10.1016/j.anai.2020.08.083 ◽

2020 ◽

Vol 125 (5) ◽

pp. S21

Author(s):

A. Banerji ◽

J. Hao ◽

M. Yu ◽

J. Bernstein ◽

D. Johnston ◽

...

Keyword(s):

Extension Study ◽

Efficacy And Safety ◽

Term Efficacy ◽

Open Label Extension

Download Full-text

Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial

Allergy Asthma & Clinical Immunology ◽

10.1186/s13223-020-0409-3 ◽

2020 ◽

Vol 16 (1) ◽

Author(s):

Donald S. Levy ◽

Henriette Farkas ◽

Marc A. Riedl ◽

Florence Ida Hsu ◽

Joel P. Brooks ◽

...

Keyword(s):

Subgroup Analysis ◽

Hereditary Angioedema ◽

Efficacy And Safety ◽

C1 Inhibitor ◽

Phase 3 ◽

Term Efficacy ◽

Open Label Extension

Download Full-text

Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study

Modern Rheumatology ◽

10.3109/14397595.2013.865822 ◽

2013 ◽

Vol 24 (5) ◽

pp. 725-733 ◽

Author(s):

Yoshiya Tanaka ◽

Kazuhiko Yamamoto ◽

Tsutomu Takeuchi ◽

Hisashi Yamanaka ◽

Naoki Ishiguro ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Certolizumab Pegol ◽

Efficacy And Safety ◽

Term Efficacy ◽

Open Label Extension

Download Full-text